NVO Novo Nordisk AS

Novo Nordisk is a Danish pharmaceutical company and global leader in diabetes care and obesity treatment, with blockbuster GLP-1 drugs including Ozempic, Victoza, and Wegovy. Sector: Healthcare.

Novo Nordisk AS (NVO) is an individual stock. The analysis below presents key financial metrics for the company, covering profitability, capital efficiency, valuation, margins, and growth.

Looking at how effectively the company deploy capital, ROIC is 31.45%, WACC is 5.81%, and the economic spread is 25.64%. On balance, the company is earning returns on capital well in excess of what investors and creditors require — the defining characteristic of a high-quality compounding company. Supporting metrics show ROE at 61.81% and ROA at 18.99%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a company with credible compounding capacity if current operating execution persists.

From a pricing standpoint, the company sits at trailing P/E of 10.22, forward P/E of 11.21, PEG of 0.40. The narrow spread between trailing and forward multiples implies earnings expectations are relatively stable — the company is not being priced for an earnings inflection. Growth-adjusted valuation is compelling at this PEG level — the multiple appears reasonable given the expected earnings trajectory. A current ratio reading of 0.80 suggests the company carries less short-term financial cushion than the broader market average. In total, the multiple and liquidity readings describe a company where valuation is a secondary risk relative to earnings delivery — the numbers are defensible if estimates hold.

Across the three margin layers, gross margin sits at 81.69%, operating margin at 43.40%, and free cash flow margin at 14.00%. The gross margin reading is exceptional — a reliable indicator of competitively advantaged businesses. Operating margins this strong typically indicate a combination of pricing power, cost discipline, and operating leverage. At this level, free cash flow generation is present but not a defining strength of the company's underlying businesses. This margin configuration supports a cautious interpretation: profitability exists, though durability is less certain under stress.

On a forward-looking basis, TTM revenue growth of 6.43% a signal of steady demand without the volatility of high-growth names, while the estimated 12-month price change of 37.46%, where consensus pricing assumptions suggest sizable appreciation potential. Revenue growth and price targets are correlated but not the same — strong operations do not always translate to strong price appreciation, and vice versa. The forward return case rests on whether the company can sustain their operating trajectory long enough for analyst price targets to be reached or exceeded. The estimated 12-month price change is based on analyst consensus price target estimates, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

The full scorecard here is hard to argue with: capital efficiency is strong, margins are healthy, and growth is being priced constructively.

This summary is based on publicly available quantitative data and is not intended as investment advice. Carefully consider your personal financial circumstances before making any decisions.